Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1697 clinical trials
None
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

  • 1 views
  • 27 Jun, 2021
  • 1 location
None
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

bendamustine
neutrophil count
tumor burden
platelet count
rituximab
  • 37 views
  • 06 Sep, 2021
  • 37 locations
None
  • 0 views
  • 11 Sep, 2021
  • 26 locations
None
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

cyclophosphamide
ct scan
peripheral t-cell lymphoma
measurable disease
etoposide
  • 3 views
  • 21 Jan, 2021
  • 1 location
None
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.

stanford v regimen
refractory hodgkin lymphoma
lymphoma
platelet count
  • 19 views
  • 07 Nov, 2020
  • 2 locations
None
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 …

lymphoma
mycosis
  • 0 views
  • 07 Nov, 2020
  • 1 location
None
High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement

This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and

methotrexate
cancer
chemoimmunotherapy
  • 4 views
  • 07 Nov, 2020
  • 1 location
None
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be

bexarotene
interferon
mycosis
cancer
phototherapy
  • 112 views
  • 08 Nov, 2020
  • 1 location
None
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

and followed by lenalidomide maintenance in newly-diagnosed primary intraocular lymphoma. Progression free survival (PFS) of the cohort is the primary endpoint.

  • 0 views
  • 23 Jan, 2021
  • 1 location